for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Idera Pharmaceuticals Inc

IDRA.OQ

Latest Trade

0.94USD

Change

-0.02(-2.53%)

Volume

153,776

Today's Range

0.92

 - 

0.97

52 Week Range

0.92

 - 

6.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.96
Open
0.96
Volume
153,776
3M AVG Volume
10.64
Today's High
0.97
Today's Low
0.92
52 Week High
6.11
52 Week Low
0.92
Shares Out (MIL)
52.76
Market Cap (MIL)
49.60
Forward P/E
-1.79
Dividend (Yield %)
--

Next Event

Q3 2021 Idera Pharmaceuticals Inc Earnings Release

Latest Developments

更多

Idera Pharmaceuticals Reports QTRLY Loss Per Share Of $0.14

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial Of Tilsotolimod + Ipilimumab In Anti-PD-1 Refractory Advanced Melanoma

Idera Pharmaceuticals Posts Q4 Loss Per Share $2.11

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Idera Pharmaceuticals Inc

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.

Industry

Biotechnology & Drugs

Contact Info

505 Eagleview Blvd Ste 212

EXTON, PA

19341-1199

United States

+1.484.3481600

http://www.iderapharma.com/

Executive Leadership

James A. Geraghty

Independent Chairman of the Board

Vincent J. Milano

President, Chief Executive Officer, Director

John J. Kirby

Chief Financial Officer, Senior Vice President

Daniel B. Soland

Chief Operating Officer, Senior Vice President

Bryant David Lim

Senior Vice President, General Counsel, Corporate Secretary

Key Stats

3.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.250

2019

-2.960

2020

-3.330

2021(E)

-0.540
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.30
Price To Cash Flow (TTM)
4.53
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
33.28
Return on Equity (TTM)
27.58

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up